"Buzz on the Street" Show: Pressure Biosciences (OTCQB: PBIO) Coverage By Zacks Small Cap Research | Financial Buzz

“Buzz on the Street” Show: Pressure Biosciences (OTCQB: PBIO) Coverage By Zacks Small Cap Research

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Zacks Small Cap Research (“Zacks SCR”) has initiated coverage on the Company.

Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report that between 1950 and 2017, there were a total of 359 new diseases and injuries added to the fatal and non-fatal list of conditions. Some of the most common cases include cancer, heart conditions, stroke, respiratory infections, lung diseases, Alzheimer’s, diabetes, and kidney diseases. While some of these conditions are unpreventable, conditions such as cancer and heart issues can be resolved or their spread slowed with innovative treatment and medicine. For instance, patients suffering from cancer typically undergo therapies such as chemotherapy or radiotherapy. Chemotherapy and radiotherapy are two of the most common cancer treatments and are aimed towards prolonging life expectancy, controlling or eradicating malignant cells. And despite its effectiveness, biotechnology companies are continuing to develop new and innovative treatments such as targeted therapies or personalized treatments. Nonetheless, while biotechnology companies are progressing within the industry, each year more and more cases of medical conditions are emerging throughout the world. However, some regions tend to have a more developed healthcare system and can immediately address the needs of their patients. On the other hand, underdeveloped regions typically lack adequate access to proper healthcare, which ultimately results in a large number of fatalities and untreated people. The IHME said in 2017 that regions such as CanadaJapanAustralia, and western Europe had the highest life expectancies. Meanwhile, the central and southern regions in Africa had the lowest life expectancies. And despite the disparities between the developed and underdeveloped regions, biotechnology companies are slowly moving towards addressing the overall global matter. According to data compiled by Global Market Insights, the global biotechnology market was valued at USD 399.4 Billion in 2017 and is expected to witness a CAGR of 9.9% from 2018 to 2024. 

Customarily, most cancer patients receive similar treatment depending on their specific type of cancer and the stage progression. However, researchers began to notice that treatments were more effective for some people, while others received experienced little to no response. As such, researchers realized that genetics differences in each patient can influence how they respond to the treatment. For instance, a patient who can process medicine much faster than others would likely require a higher dose of medicine for it to be effective. Moreover, some patients experience severe side effects from specific cancer drugs, making the process unbearable. And in certain instances, doctors will either prescribe an additional medicine or lower the dosage to reduce the painful side effects. Overall, the evolution of personalized treatments has completely reshaped how medical practitioners approach cancer therapy. Notably, researchers have begun to collect tissue samples in order to search for and better understand potential cancer biomarkers. Specifically, formalin-fixed paraffin-embedded (FFPE) and fresh frozen biopsy tissue samples have become widely practiced methods in clinical preservation. Generally, researchers use these tissues to search for specific proteins which can then be used as a diagnosis to indicate which cancer drugs would be the most effective, according to Biochain. Furthermore, biotechnology researchers can accelerate discoveries of new therapies and drugs that can be used towards curing or slowing cancers. “We have yet to realize the full potential of precision medicine, but we are making significant headway,” said Eva Kiesler, former Senior Science Editor at Memorial Sloan-Kettering Cancer Center, and Meredith Begley, Health and Medical writer at Memorial Sloan-Kettering Cancer Center. “Options for many people with cancer have dramatically improved through targeted therapies that reverse the effects of specific gene mutations in their tumor cells.”

For more information, please visit: Pressure Biosciences, Inc.

For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure


  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pressure biosciences, inc, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.